Pursuant to the Food and Drug Administration Safety and Innovation Act (FDASIA) signed into law on July 9, 2012, the Food and Drug Administration
Today I am focusing on the self-referral ban under the federal Stark laws. In particular, a recent case - Fresenius Medical Care Holdings, Inc. v
A New Jersey appellate court is set to determine the fate of a controversial measure by the state's environmental regulator to waive land use
Now that the new year is upon us, today's post will look at the Department of Health and Human Services' Office of Inspector General (OIG), in particular
Compliance officials have a great deal to worry about. They are judged by results and loaded with stress over the latest changes in government guidance
Today, I was intrigued by a Washington Post article about branded drug companies offering discount coupons to stave off competition from generic drug manufacturers.
Recent press releases provide notice of activities that draw the government's ire -- and result in serious criminal consequences.
The 7th Circuit Court of Appeals recently issued a decision of interest to physicians and teaching hospitals. It concerns the method of rotating teaching physicians between multiple surgeries and billing Medicare for those services.
Physicians who reassign their right to bill the Medicare program can still be liable for false claims submitted by the entities who obtained that reassignment, as discussed in a recent "Alert" issued by the Office of Inspector General (OIG).
Both the federal Food and Drug Administration (FDA) and Office of the Inspector General (OIG) have authority to seek personal consequences against corporate officers deemed responsible for federal health care violations.